Venous thromboembolism Trials in Vienna, Austria
Conditions / Venous thromboembolism / Vienna, Austria
Research into Venous thromboembolism spans multiple therapeutic approaches and trial phases.
29 total trials for this combination
Showing top 10 of 29 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00571649 | Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients | COMPLETED | PHASE3 |
| NCT02064439 | Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) | COMPLETED | PHASE3 |
| NCT00694382 | Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy | COMPLETED | PHASE3 |
| NCT00329628 | Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin | COMPLETED | PHASE3 |
| NCT02234843 | EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis | COMPLETED | PHASE3 |
| NCT05171049 | A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE | TERMINATED | PHASE3 |
| NCT02464969 | Apixaban for the Acute Treatment of Venous Thromboembolism in Children | COMPLETED | PHASE4 |
| NCT00986154 | Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). | COMPLETED | PHASE3 |
| NCT00439725 | Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study | COMPLETED | PHASE3 |
| NCT05171075 | A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE | TERMINATED | — |